Trial Profile
Clinical pharmacology study of NIK-333-Search for drug-response gene and examination of safety in patients who were completely cured of hepatitis C virus-positive hepatocellular carcinoma -
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Peretinoin (Primary)
- Indications Hepatitis C; Liver cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Kowa
- 03 Jun 2016 New trial record